Learning Tracks

This session will provide presentations on best practices for post-approval chemistry, manufacturing, and controls (CMC) and bioequivalence (BE) changes. Discussion and cases will include addressing areas needing guidance including post-approval changes to complex dosage forms such as Transdermal patches, MDI, DPI, and peptide drug products. The panel will specifically address potential and desired changes to the SUPAC guidance.